

## CLAIM AMENDMENTS

1           1. (Original) A pharmaceutical formulation, administered  
2 orally after dispersing in water at therapeutic doses which  
3 comprises of,

4           a. alendronate microparticles coated with a polymer  
5 insoluble at pH 6 - 7.5, and alginic acid or sodium alginate or  
6 admixtures there of, where

7           b. alendronate dissolves in 900 ml 0.1 N HCl at the rate  
8 of not less than 85% of within 30 minutes at the range of pH 1 - 4,

9           c. the dispersion in a glass of 250 ml. water at the  
10 degree of 25°C contains no dissolved alendronate at pH 6 - 7.5 or  
11 at the most 10% w/v of alendronate dissolved in 3 minutes.

1           2. (original) The pharmaceutical formulation as claimed  
2 in claim 1, comprises lubricants, diluents, flavors and sweeteners  
3 or their mixture thereof.

1           3. (original) The pharmaceutical formulation as claimed  
2 in claim 2, where in the diluent is preferably selected from  
3 lactose and microcrystalline cellulose or admixtures thereof.

1           4. (Currently amended) The pharmaceutical formulation as  
2 claimed in claim 2, where in the sweetener is selected from  
3 aspartame, potassium acesulfame, monoammonium glycyrrhizinate,  
4 sodium saccharine, sucrose and its derivatives, ~~polioles~~ polyols  
5 and their derivatives, are preferably used alone or in combination.

1           5. (original) The pharmaceutical formulation as claimed  
2 in claim 1, where in the polymers are selected from, preferably  
3 polymethacrylates, polyvinyl acetate diethylaminoacetate and poly  
4 butyl methacrylate / 2-dimethylamino-ethyl methacrylate/methyl  
5 methacrylate copolymers or their mixtures thereof.

1           6. (original) The pharmaceutical formulation as claimed  
2 in claim 1, where in the polymers are, Poly(butyl methacrylate, (2-  
3 dimethyl aminoethyl) methacrylate, methyl methacrylate) 1:2:1 is  
4 preferred.

1           7. (original) The pharmaceutical formulation as claimed  
2 in claim 1, which is dispersed in a glass of 250 ml water at the  
3 degree of 25°C at pH 6 - 7.5, contains alendronate in between  
4 0.001% w/v - 3% w/v.

1           8. (original) The pharmaceutical formation as claimed in  
2 claim 1 where in the alendronate is alendronate monosodium  
3 trihydrate or pharmaceutically acceptable derivatives.

1           9. (original) The pharmaceutical formulation as claimed  
2 in claim 1, which is dispersed in a glass of 250 ml. water at the  
3 degree of 25°C at pH 6 - 7.5, contains alginic acid or sodium  
4 alginate or their mixtures in between 0.001% w/v - 2% w/v.

1           10. (New) A pharmaceutical formulation, which is orally  
2 administered after dispersing in water, which comprises:  
3 alendronate microparticles coated with a polymer insoluble at pH 6  
4 to 7.5, wherein the polymer comprises polybutyl methacrylate,  
5 (2-dimethylaminoethyl)methacrylate and methyl methacrylate in a  
6 1:2:1 ratio; alginic acid or sodium alginate or admixtures thereof;  
7 sucrose and sodium saccharine as sweeteners; microcrystalline  
8 cellulose as diluent; and colloidal silica as a lubricant, wherein  
9 the alendronate dissolves in 900 ml of 0.1N HCl at a rate of not  
10 less than 85% within 30 minutes at a pH of 1 to 4, and wherein the  
11 resulting dispersion in water at 25°C contains either no dissolved  
12 alendronate at a pH of 6 to 7.5, or at most 10% w/of dissolved  
13 alendronate after 3 minutes.